MedTrace Logo

Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism

NCT01067365 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2014-06-27

No results posted yet for this study

Summary

Subjects who completed ZA-003 were eligible to receive an additional year of treatment in this extension study.

Conditions

  • Secondary Hypogonadism

Interventions

DRUG

Androxal

12.5 mg once daily

DRUG

Androxal

25 mg once daily

Sponsors & Collaborators

  • Repros Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Andre van As, MD, PhD · Repros Therapeutics Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
68 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2007-05-31
Completion
2007-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01067365 on ClinicalTrials.gov